A previous study of 338 advanced cancer patients in the USA and Europe showed that, although the median overall survival in HER2-positive patients (13.9 versus 11.4 months, p = 0.047) was higher in the univariate analysis, the prognostic value was not observed in multivariate analysis [43]. The gene discussed is ERBB2; the disease is cancer.